Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 238,670,721 papers from all fields of science
Search
Sign In
Create Free Account
FLT3 Inhibitor
Known as:
Receptor-Type Tyrosine-Protein Kinase FLT3 Protein Inhibitor
Any drug or substance that inhibits the activity of receptor-type tyrosine-protein kinase FLT3 protein.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Flt3 inhibitors for improving pain treatments by opioids
J. Valmier
,
C. Rivat
,
P. Sokoloff
2018
Corpus ID: 204066552
Inventors have evaluated the effects of the FLT3 inhibitors on morphine analgesic potency, on tolerance to morphine analgesia and…
Expand
2018
2018
Estudi del perfil d'expressió de les histones deacetilasa (hdac) en pacients pediàtrics amb leucèmia aguda
N. García
2018
Corpus ID: 87893625
Antecedents: els inhibidors d’histona deacetilasa (HDACi) han emergit els ultims anys com potencials tractaments dirigits, amb la…
Expand
2017
2017
Experimental FLT3 Inhibitor May Benefit Patients with Refractory AML
J. Schieszer
2017
Corpus ID: 155155362
An FLT3 inhibitor, gilteritinib, has been found to result in more frequent and sustained responses in patients with relapsed…
Expand
2015
2015
Abstract 2631: Discovery of SC110237, a highly potent, selective and orally active FLT3 inhibitor for the treatment of acute myeloid leukemia
Norman Kong
,
Daxing Gao
,
He-Ping Yang
,
Ya-Jun Yu
2015
Corpus ID: 78538075
FLT3 (Fms-like tyrosine kinase 3) is the most frequently mutated gene in acute myeloid leukemia (AML). Activating Flt3 mutations…
Expand
2014
2014
Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies
W. Czardybon
,
R. Windak
,
+10 authors
K. Brzózka
2014
Corpus ID: 54160775
PIM kinases represent an emerging therapeutic target in multiple hematological malignancies, as exemplified by currently ongoing…
Expand
2014
2014
MYELOID NEOPLASIA MUC 1-C oncoprotein promotes FLT 3 receptor activation in acute myeloid leukemia cells
Sui-Yang Liu
,
Yin Li
,
+7 authors
R. Stone
2014
Corpus ID: 44206028
The FMS-like tyrosine kinase 3 (FLT3) receptor is a member of the class III subfamily that includes the FMS, KIT, and PDGF…
Expand
2011
2011
AC220, a Potent and Specific FLT3 Inhibitor, Enhances the Activity of Combined Cytarabine and Daunorubicin Chemotherapy in a FLT3-ITD Model of AML
B. Belli
,
Alan Dao
,
W. Wierenga
,
R. Armstrong
2011
Corpus ID: 58465945
Abstract 1538 Acute myeloid leukemia patients harboring an activated FLT receptor have a poorer prognosis following standard…
Expand
2009
2009
Lestaurtinib as a FLT3 inhibitor
A. Burnett
2009
Corpus ID: 82764190
Overexpression of the FLT-3 receptor is common in Acute Myeloid Leukaemia (AML) and mutations represent one of the commonest…
Expand
2008
2008
Genetics: In the driving seat
Simone Alves
Nature Reviews. Cancer
2008
Corpus ID: 37151357
membrane and kinase domains of the receptor tyrosine kinase FLT3 are known to be leukaemogenic, but can other mutations in FLT3…
Expand
2005
2005
Modulation of FLT3 Inhibitor-induced Cytotoxicity in Acute Myeloid Leukemia by FLT3 Ligand
J. Bryan
2005
Corpus ID: 68792326
This project was developed in coordination with the larger study “FL Attenuates FLT3 inhibitor effects in AML” being conducted by…
Expand